2016 ACC AHA Dual Antplatelet Therapy in CAD Q5

2016 ACC AHA Dual Antplatelet Therapy in CAD
http://circ.ahajournals.org/content/134/10/e123

According to the “2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease,” p e133

“In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after BMS or DES implantation, P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) should be given for at least
_________.”

a) 6 months
b) 9 months
c) 12 months
d) 24 months

click here for answer

(C)

“In patients with ACS (NSTE-ACS or STEMI) treated
with DAPT after BMS or DES implantation, P2Y12
inhibitor therapy (clopidogrel, prasugrel, or ticagrelor)
should be given for at least 12 months.1”

Leave Comment

Your email address will not be published. Required fields are marked *